Pitavastatin Calcium Confers Fungicidal Properties to Fluconazole by Inhibiting Ubiquinone Biosynthesis and Generating Reactive Oxygen Species
Open accessThe DOI matches its Crossref record; 79 of the 80 references it cites were found in a registry or an index; 37 of the 67 sources its claims cite were checked for support.
Abstract
Fluconazole (FLC) is extensively employed for the prophylaxis and treatment of invasive fungal infections (IFIs). However, the fungistatic nature of FLC renders pathogenic fungi capable of developing tolerance towards it. Consequently, converting FLC into a fungicidal agent using adjuvants assumes significance to circumvent FLC resistance and the perpetuation of fungal infections. This drug repurposing study has successfully identified pitavastatin calcium (PIT) as a promising adjuvant for enhancing the fungicidal activity of FLC from a comprehensive library of 2372 FDA-approved drugs. PIT could render FLC fungicidal even at concentrations as low as 1 μM. The median lethal dose (LD50) of PIT was determined to be 103.6 mg/kg. We have discovered that PIT achieves its synergistic effect by inhibiting the activity of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, thereby impeding ubiquinone biosynthesis, inducing reactive oxygen species (ROS) generation, triggering apoptosis, and disrupting Golgi function. We employed a Candida albicans strain that demonstrated a notable tolerance to FLC to infect mice and found that PIT effectively augmented the antifungal efficacy of FLC against IFIs. This study is an illustrative example of how FDA-approved drugs can effectively eliminate fungal tolerance to FLC.
Overview
CoChat Summary
TL;DR
A screen of 2372 FDA-approved drugs identified pitavastatin calcium (PIT) as a fluconazole (FLC) adjuvant that converts FLC from fungistatic to fungicidal at low concentrations. PIT acts by inhibiting HMG-CoA reductase/ubiquinone biosynthesis, increasing ROS and apoptosis, disrupting Golgi function, and improving outcomes in mice infected with highly FLC-tolerant Candida albicans.
Key findings
- From 2372 FDA-approved drugs, 222 prevented C. albicans recovery with 4 μg/mL FLC; after excluding 22 known antifungals, 200 were tested, 30 made FLC fungicidal below 12.5 μM, and 12 did so at ≤3.125 μM with FLC ≤4 μg/mL. Eight compounds cleared FLC tolerance in disk diffusion assays across four strains.
- PIT had an LD50 of 103.6 mg/kg, compared with 19 mg/kg for GdA and 42 mg/kg for CsA. With 1 μM PIT, FLC MIC decreased from 1 to 0.5 μg/mL and MFC decreased from not detected up to 64 μg/mL to 2 μg/mL, giving MFC/MIC = 4. PIT also rendered voriconazole, ketoconazole, itraconazole, and miconazole fungicidal.
- PIT targeted HMG-CoA reductase/Hmg1: HMG1/hmg1Δ, ERG8/erg8Δ, and IDI1/idi1Δ mutants were more susceptible to 4 μM PIT; HMG1 overexpression and exogenous mevalonate mitigated PIT. PIT + FLC increased intracellular and mitochondrial ROS about 2-fold, upregulated MCA1 about 7-fold vs control and 2.5-fold vs FLC alone, upregulated CYC3 about 15.7-fold vs control and 4.3-fold vs FLC alone, and increased caspase activity nearly 2-fold vs FLC alone. Ergosterol plus ubiquinone together reversed the synergistic lethality.
- In mice infected with high FLC-tolerant cmp1-aidΔ/cmp1-aidΔ, FLC 1 mg/kg + PIT 0.5 mg/kg reduced kidney fungal burden (p = 0.0032 at day 6; p = 0.0023 at day 10). With clinical isolate 283, FLC 4 mg/kg + PIT 1 or 3 mg/kg reduced kidney burden (p = 0.0192 and p = 0.0054). Mortality over 30 days was 60% in controls, 50% with FLC alone, and 10% with FLC + PIT 3 mg/kg (p = 0.0204 vs control; p = 0.0477 vs FLC).
Methods
- High-throughput screen of 2372 FDA-approved drugs at 100 μM with 4 μg/mL FLC against C. albicans SC5314, followed by broth microdilution, dose–matrix titration, disk diffusion, spotting, MFC determination, qRT-PCR, gene deletion/overexpression, ROS measurement, caspase assay, and membrane permeability assays.
- Acute toxicity was assessed by the OECD 425 Up-and-Down procedure via intraperitoneal administration in mice to determine LD50.
- Murine invasive candidiasis used female C57BL/6 mice (6–8 weeks old, 17–19 g) infected by tail vein with C. albicans strains or clinical isolate 283; FLC ± PIT was given intraperitoneally for 3 days, with survival monitored for 30 days, fungal burden measured in spleen/liver/kidney, and histopathology performed. Statistical analyses included two-tailed unpaired t-tests, Kaplan–Meier curves, and log-rank tests.
Limitations
- Stated in the paper: “this study did not directly measure intracellular ergosterol levels,” although ergosterol-synthesis inhibition was supported by mevalonate rescue and gene-expression data.
- Evident from the text: the in vivo work is limited to mouse models, with fungal-burden analyses using six mice per group and survival analyses using ten mice per group; no human clinical data are reported.
- Evident from the text: the mechanism is inferred largely from genetic susceptibility, overexpression, and metabolite-rescue experiments; direct enzymatic measurement of Hmg1 activity or direct quantification of ubiquinone levels is not reported.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures











Verification
Claims the paper makes
23 Valid · 3 Not valid · 7 Not checked · 95 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Augmenting intracellular ROS levels in C. albicans offers a promising strategy for achieving fungicidal outcomes, like applying amphotericin B and miconazole, ultimately leading to cell demise [55].”
§ Pitavastatin Calcium Confers Fungicidal Properties to Fluconazole by Inhibiting Ubiquinone Biosynthesis and Generating Reactive Oxygen Species > 3. Results > 3.6. The Combination of PIT and FLC Elicits Reactive Oxygen Species (ROS) Generation by Inhibiting Ubiquinone Production
What the sources say
- Supportedcites [55] Belenky, 2013, Fungicidal drugs induce a common oxidative-damage cellular death pathway, Cell Rep. source
The Introduction (page not provided) states that amphotericin B and miconazole induce a pathway in C. albicans that culminates in lethal ROS formation. The Results section, “Fungicide-Dependent ROS Production Leads to Fungal Cell Death” (page not provided), reports ROS induction after fungicidal treatment and identifies ROS as critical to drug-induced death. This supports the claim’s hedged description of a promising fungicidal strategy. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These observations suggested that PIT targets HMG-CoA reductase encoded by the HMG1 (C1_03780C_A) gene in C. albicans [50].”
§ Pitavastatin Calcium Confers Fungicidal Properties to Fluconazole by Inhibiting Ubiquinone Biosynthesis and Generating Reactive Oxygen Species > 3. Results > 3.5. PIT Makes FLC Fungicidal Depending on Targeting HMG-CoA Reductase
What the sources say
- Partly supportedcites [50] Callegari, 2010, Atorvastatin-induced cell toxicity in yeast is linked to disruption of protein isoprenylation, FEMS Yeast Res. sourceExperimental — accuracy not yet measured
The Introduction (page not provided) identifies HMG-CoA reductase as the molecular target of statins, and the sterol-synthesis results section links atorvastatin toxicity to its inhibition in S. cerevisiae. The paper does not establish that PIT targets the enzyme in C. albicans or identify its HMG1 gene (C1_03780C_A). (LLM, conf=0.88)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“It is imperative to render FLC fungicidal to effectively manage IFIs, as an increase in FLC tolerance leads to FLC resistance [10] and persistent candidemia [11,12].”
§ Pitavastatin Calcium Confers Fungicidal Properties to Fluconazole by Inhibiting Ubiquinone Biosynthesis and Generating Reactive Oxygen Species > 1. Introduction
What the sources say
- Partly supportedcites [11] Rosenberg, 2018, Antifungal tolerance is a subpopulation effect distinct from resistance and is associated with persistent candidemia, Nat. Commun. sourceExperimental — accuracy not yet measured
In the section “Persistent candidemia is associated with highly tolerant isolates,” isolates from persistent infections had higher FLC tolerance than isolates from infections cleared by treatment. The paper describes a correlation; it does not establish that an increase in tolerance causes persistent candidemia. Page numbers are not available in the supplied passages. (LLM, conf=0.88)
- Partly supportedcites [12] Levinson, 2021, Impact of tolerance to fluconazole on treatment response in Candida albicans bloodstream infection, Mycoses sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) reports that fluconazole tolerance was associated with failure to eradicate bloodstream Candida infections in patients, which supports a link to persistent candidemia. The Discussion (page unavailable) reports that tolerance predicted treatment failure in patients treated within 24 hours, but the paper does not establish that increasing tolerance causes persistent candidemia. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Nevertheless, the fungistatic nature of FLC renders pathogenic fungi capable of developing tolerance, characterized by FLC-susceptible fungal strains surviving at FLC concentrations higher than the minimum inhibitory concentration (MIC) [9].”
§ Pitavastatin Calcium Confers Fungicidal Properties to Fluconazole by Inhibiting Ubiquinone Biosynthesis and Generating Reactive Oxygen Species > 1. Introduction
What the sources say
- Partly supportedcites [9] Berman, 2020, Drug resistance and tolerance in fungi, Nat. Rev. Microbiol. sourceExperimental — accuracy not yet measured
The Introduction defines tolerance as growth of drug-susceptible fungal strains above the MIC, and says antifungal tolerance is most evident with fungistatic drugs. The paper discusses fluconazole-tolerant cells, but does not establish that fluconazole’s fungistatic nature itself causes pathogenic fungi to develop tolerance. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Although certain adjuvants, such as CsA and GdA, can make FLC fungicidal in laboratory studies, their clinical applications are limited due to their high toxicity [43,44].”
§ Pitavastatin Calcium Confers Fungicidal Properties to Fluconazole by Inhibiting Ubiquinone Biosynthesis and Generating Reactive Oxygen Species > 3. Results > 3.3. PIT Has Low Toxicity
What the sources say
- Not checked — no full text of the sourcecites [43] Patocka, 2021, Cyclosporine A: Chemistry and Toxicity—A Review, Curr. Med. Chem. source
- Partly supportedcites [44] Sanchez, 2020, Old and New Approaches to Target the Hsp90 Chaperone, Curr. Cancer Drug Targets sourceExperimental — accuracy not yet measured
The “Natural Products and their Derivatives” section says GdA is a poor clinical candidate partly because of in vivo toxicity. It does not establish the same limitation for CsA; the passages found concern Hsp90 inhibitors in cancer, not the clinical use of either agent with fluconazole. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
79 more claims · 5 with their cited sources checked
Create a free account to see all 128 claims and every source verdict.
- It may state two separate claims as one. 32
- Probably not a substantial claim. 15
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“the cmp1-aidΔ/cmp1-aidΔ mutant, with the C-terminal 110 residues of Cmp1 deleted, exhibits high FLC tolerance51”
From Impairing the interaction between Erg11 and cytochrome P450 reductase Ncp1 enhances azoles’ antifungal activities (2025) · cites this paper as [51]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Pitavastatin Calcium Confers Fungicidal Properties to Fluconazole by Inhibiting Ubiquinone Biosynthesis and Generating Reactive Oxygen Species > 2. Materials and Methods > 2.13. Murine Invasive C. albicans Infections
“along with intraperitoneal administration of PIT at doses of 1 or 3 mg/kg once a day for three consecutive days.”
§ Pitavastatin Calcium Confers Fungicidal Properties to Fluconazole by Inhibiting Ubiquinone Biosynthesis and Generating Reactive Oxygen Species > 3. Results > 3.8. PIT Enhances the Antifungal Efficacy of FLC against Invasive Candidiasis Caused by High FLC-Tolerant C. albicans Strains
“FLC (1 mg/kg) + PIT (0.5 mg/kg) significantly reduced the fungal burden in the kidney”
Citations
Cites
Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718 · cited 2×
“…(atorvastatin hydrochloride, cerivastatin sodium, cilastatin Here, we systematically evaluated the synergetic lethal , atorvastatin hemicalcium, bestatin, bestatin hydrochloride , fl uvastatin sodium, lovastatin, pentostatin, PIT, especially identifying advantages of pharmacokinetic drug [67].”
BackgroundDrug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237 · cited 2×
“FDA-approved drugs [66].”
BackgroundOxidative stress and cancer: Have we moved forward?
Halliwell, B. (2007) · Biochemical Journal · doi:10.1042/bj20061131 · Cited by 1,302 · cited 1×
“This oxidation process can lead to compromised functionality of these essential biological macromolecules, ultimately causing damage to the membrane and triggering programmed cell death in the fungal pathogen [60,61].”
BackgroundThe global problem of antifungal resistance: prevalence, mechanisms, and management
Perlin, D. S., Rautemaa-Richardson, R., & Alastruey-Izquierdo, A. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30316-x · Cited by 1,055
Antifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond
Lee, Y., Puumala, E., Robbins, N., & Cowen, L. E. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00199 · Cited by 801
Hsp90 Potentiates the Rapid Evolution of New Traits: Drug Resistance in Diverse Fungi
Cowen, L. E., & Lindquist, S. (2005) · Science · doi:10.1126/science.1118370 · Cited by 698 · cited 4×
“It is imperative to render FLC fungicidal to effectively manage IFIs, as an increase in FLC tolerance leads to FLC resistance [10] and persistent candidemia [11,12].”
BackgroundInfluentialDrug resistance and tolerance in fungi.
Berman, J., & Krysan, D. J. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0322-2 · Cited by 642 · cited 2×
“Nevertheless, the fungistatic nature of FLC renders pathogenic fungi capable of developing tolerance, characterized by FLC-susceptible fungal strains surviving at FLC concentrations higher than the minimum inhibitory concentration (MIC) [9].”
BackgroundNoble, S. M., & Johnson, A. D. (2005) · Eukaryotic Cell · doi:10.1128/ec.4.2.298-309.2005 · Cited by 592 · cited 1×
“Target gene null mutants were constructed using fusion PCR to obtain homologous recombinant sequences, as previously described [30].”
MethodCombination antifungal therapy
Johnson, M. D., MacDougall, C., Ostrosky-Zeichner, L., Perfect, J. R., & Rex, J. H. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.3.693-715.2004 · Cited by 541 · cited 1×
“These studies commonly employed the fractional inhibitory concentration index (FICI) to assess the synergy between FLC and existing drugs, with a FICI value of ≤ 0.5 indicating synergy [22].”
MethodInfluentialApoptosis induced by environmental stresses and amphotericin B in Candida albicans
Phillips, A. J., Sudbery, I., & Ramsdale, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2332326100 · Cited by 398 · cited 1×
“This oxidation process can lead to compromised functionality of these essential biological macromolecules, ultimately causing damage to the membrane and triggering programmed cell death in the fungal pathogen [60,61].”
BackgroundPfaller, M. A., Sheehan, D. J., & Rex, J. H. (2004) · Clinical Microbiology Reviews · doi:10.1128/cmr.17.2.268-280.2004 · Cited by 352
Sanglard, D., Ischer, F., Marchetti, O., Entenza, J., & Bille, J. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03495.x · Cited by 350 · cited 4×
“Removing the C-terminal autoinhibitory domain of Cmp1 can convert calcineurin into a constitutively activated complex [34,38,39].”
BackgroundMethodInfluentialCalcineurin is essential for survival during membrane stress in Candida albicans
Cruz, M. C., Goldstein, A. L., Blankenship, J. R., Del Poeta, M., Davis, D., Cardenas, M. E., Perfect, J. R., McCusker, J. H., & Heitman, J. (2002) · The EMBO Journal · doi:10.1093/emboj/21.4.546 · Cited by 342 · cited 2×
“…had been previously identified as having direct antifungal effects or fungicidal effects, including a polyene (Amphotericin B) [33], 15 azoles [7], 3 TOR inhibitors (Rapamycin, Everolimus, and Temsirolimus) [11,15], and 2 calcineurin inhibitors (Cyclosporin A and Tacrolimus) [34,35] (Table S3).”
BackgroundLaFayette, S. L., Collins, C., Zaas, A. K., Schell, W. A., Betancourt-Quiroz, M., Gunatilaka, A. A. L., Perfect, J. R., & Cowen, L. E. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1001069 · Cited by 329 · cited 2×
“The FLC inhibition zones were clear when the YPD solid medium was supplemented with FLC synergistic lethal adjuvants such as GdA and CsA [34,37].”
BackgroundMethodShafiei, M., Peyton, L., Hashemzadeh, M., & Foroumadi, A. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104240 · Cited by 295 · cited 2×
“While novel approaches may offer potential solutions for treating IFIs [5,6], azoles, functioning as inhibitors of lanosterol 14-α demethylase, continue to hold paramount importance as clinically approved antifungal medications for managing these infections [7].”
BackgroundRosenberg, A., Ene, I. V., Bibi, M., Zakin, S., Segal, E. S., Ziv, N., Dahan, A. M., Colombo, A. L., Bennett, R. J., & Berman, J. (2018) · Nature Communications · doi:10.1038/s41467-018-04926-x · Cited by 270 · cited 9×
“However, recent studies have suggested high FLC tolerance levels contribute to persistent candidemia [11,12].”
BackgroundMethodInfluentialWang, Y., & Hekimi, S. (2016) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.12.007 · Cited by 256 · cited 1×
“The reduction in ubiquinone levels subsequently results in the production of ROS and the impairment of mitochondrial function [59], potentially explaining the increased ROS production caused by PIT.”
BackgroundStructural mechanism of ergosterol regulation by fungal sterol transcription factor Upc2
Yang, H., Tong, J., Lee, C. W., Ha, S., Eom, S. H., & Im, Y. J. (2015) · Nature Communications · doi:10.1038/ncomms7129 · Cited by 223 · cited 1×
“Upc2 is a global ergosterol-synthesis-related gene regulator contributing to FLC tolerance [40,41].”
BackgroundFungicidal Drugs Induce a Common Oxidative-Damage Cellular Death Pathway
Belenky, P., Camacho, D., & Collins, J. J. (2013) · Cell Reports · doi:10.1016/j.celrep.2012.12.021 · Cited by 199 · cited 1×
“Augmenting intracellular ROS levels in C. albicans offers a promising strategy for achieving fungicidal outcomes, like applying amphotericin B and miconazole, ultimately leading to cell demise [55].”
BackgroundCross‐species discovery of syncretic drug combinations that potentiate the antifungal fluconazole
Spitzer, M., Griffiths, E., Blakely, K. M., Wildenhain, J., Ejim, L., Rossi, L., De Pascale, G., Curak, J., Brown, E., Tyers, M., et al. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.31 · Cited by 183
Old and New Approaches to Target the Hsp90 Chaperone
Sanchez, J., Carter, T. R., Cohen, M. S., & Blagg, B. S. J. (2020) · Current Cancer Drug Targets · doi:10.2174/1568009619666191202101330 · Cited by 183 · cited 2×
“Although certain adjuvants, such as CsA and GdA, can make FLC fungicidal in laboratory studies, their clinical applications are limited due to their high toxicity [43,44].”
BackgroundA marine microbiome antifungal targets urgent-threat drug-resistant fungi
Zhang, F., Zhao, M., Braun, D. R., Ericksen, S. S., Piotrowski, J. S., Nelson, J., Peng, J., Ananiev, G. E., Chanana, S., Barns, K., et al. (2020) · Science · doi:10.1126/science.abd6919 · Cited by 177 · cited 1×
“…∆ / ire1 ∆ ) (C1_07970C_A) genes, which play important roles in endoplasmic reticulum (ER) stress [62], and the AGE3 ( age3 ∆ / age3 ∆ ) (C1_02260C_A) gene and a haploin-sufficient mutant of SEC14 ( SEC14 / sec14 ∆ )(C5_00480C_A), both of which are important for the Golgi transport network [13,63].”
BackgroundRex, J. H., Nelson, P. W., Paetznick, V. L., Lozano-Chiu, M., Espinel-Ingroff, A., & Anaissie, E. J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.1.129 · Cited by 167 · cited 3×
“More importantly, the synergistic effect of these compounds on FLC in vitro has yet to be verified in vivo [23,24].”
BackgroundXu, W., Smith, F. J., Subaran, R., & Mitchell, A. P. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-08-0666 · Cited by 166
Arthington-Skaggs, B. A., Lee-Yang, W., Ciblak, M. A., Frade, J. P., Brandt, M. E., Hajjeh, R. A., Harrison, L. H., Sofair, A. N., & Warnock, A. D. W. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.8.2477-2481.2002 · Cited by 158 · cited 2×
“In support, several studies found no positive relationship between FLC tolerance and mortality caused by IFIs after FLC treatment [24,25].”
BackgroundUse of amphotericin B with azole antifungal drugs: what are we doing?
Sugar, A. M. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.9.1907 · Cited by 133 · cited 1×
“…22 compounds that had been previously identified as having direct antifungal effects or fungicidal effects, including a polyene (Amphotericin B) [33], 15 azoles [7], 3 TOR inhibitors (Rapamycin, Everolimus, and Temsirolimus) [11,15], and 2 calcineurin inhibitors (Cyclosporin A and Tacrolimus)…”
BackgroundCyclosporine A: Chemistry and Toxicity—A Review
Patocka, J., Nepovimova, E., Kuca, K., & Wu, W. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867327666201006153202 · Cited by 125 · cited 2×
“Although certain adjuvants, such as CsA and GdA, can make FLC fungicidal in laboratory studies, their clinical applications are limited due to their high toxicity [43,44].”
BackgroundStructural basis for species-selective targeting of Hsp90 in a pathogenic fungus
Whitesell, L., Robbins, N., Huang, D. S., McLellan, C. A., Shekhar-Guturja, T., LeBlanc, E. V., Nation, C. S., Hui, R., Hutchinson, A., Collins, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08248-w · Cited by 124 · cited 2×
“The upregulation of Cyc3 suggests the release of cytochrome c and the activation of metacaspase within the mitochondria [57].”
BackgroundMendoza, I., Quintero, F. J., Bressan, R. A., Hasegawa, P. M., & Pardo, J. M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.38.23061 · Cited by 115 · cited 1×
“Removing the C-terminal autoinhibitory domain of Cmp1 can convert calcineurin into a constitutively activated complex [34,38,39].”
BackgroundChin, N. X., Weitzman, I., & Della-Latta, P. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.4.850 · Cited by 101 · cited 2×
“It has been observed that statins are beneficial for FLC against For example, fl uvastatin acts synergistically with FLC against Candida species [73–75], including FLC-resistant strains of C. albicans and C. tropicalis [74,76].”
BackgroundMeletiadis, J., Antachopoulos, C., Stergiopoulou, T., Pournaras, S., Roilides, E., & Walsh, T. J. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00345-07 · Cited by 100 · cited 1×
“Consequently, the ratio of MFC to MIC in the presence of 1 µ M PIT was 4 (Figure 5A), which aligns with the established definition of fungicidal activity (MFC/MIC ≤ 4) [48,49].”
MethodLu, H., Hong, T., Jiang, Y., Whiteway, M., & Zhang, S. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114960 · Cited by 89 · cited 1×
“Invasive fungal infections (IFIs) present a significant health hazard to patients receiving hospital care, resulting in heightened rates of illness and death among individuals undergoing intricate surgical interventions or experiencing compromised immune function [1].”
BackgroundSelf-citationNyilasi, I., Kocsubé, S., Krizsán, K., Galgóczy, L., Pesti, M., Papp, T., & Vágvölgyi, C. (2010) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2010.01972.x · Cited by 83 · cited 3×
“It has been observed that statins are beneficial for FLC against For example, fl uvastatin acts synergistically with FLC against Candida species [73–75], including FLC-resistant strains of C. albicans and C. tropicalis [74,76].”
BackgroundCandida albicans targets that potentially synergize with fluconazole
Lu, H., Shrivastava, M., Whiteway, M., & Jiang, Y. (2021) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2021.1884641 · Cited by 81 · cited 2×
“Fluconazole (FLC) is a prominent antifungal azole that is extensively utilized in clinical practice owing to its wide-ranging antifungal activity, remarkable safety record, and diverse modes of administration [8].”
BackgroundSelf-citationHMG-CoA reductase inhibitors and coenzyme Q10
Nawarskas, J. J. (2005) · Cardiology in Review · doi:10.1097/01.crd.0000154790.42283.a1 · Cited by 80 · cited 1×
“PIT specifically targets HMG-CoA and inhibits mevalonate production, a precursor for both ubiquinone and ergosterol [58].”
BackgroundRobbins, N., Spitzer, M., Yu, T., Cerone, R. P., Averette, A. K., Bahn, Y.-S., Heitman, J., Sheppard, D. C., Tyers, M., & Wright, G. D. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.10.018 · Cited by 78 · cited 2×
“…were repurposed to treat fungal infections [17,68]. of an old FDA-approved drugs previously identified for FLC adjuvants were fungal For example, ibuprofen, a non-steroidal anti-in fl ammatory drug, demonstrated synergy with FLC against C. albicans in vitro and in vivo [69–72]. infections [17,68].”
BackgroundSimvastatin reduces ergosterol levels, inhibits growth and causes loss of mtDNA in Candida glabrata
Westermeyer, C., & Macreadie, I. G. (2007) · FEMS Yeast Research · doi:10.1111/j.1567-1364.2006.00194.x · Cited by 73 · cited 1×
“Many studies suggested that statins can cause mitochondrial dysfunction and stimulate the generation of ROS production [50,54].”
BackgroundTavakkoli, A., Johnston, T. P., & Sahebkar, A. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107483 · Cited by 73 · cited 1×
“…hypothesis that PIT may possess alternative antifungal mechanisms in addition to its role as an inhibitor of ergosterol synthesis by targeting Hmg1 [53]. fungicidal on the reduction in ergosterol, we propose that the supplementation of ergosterol could mitigate the transition of FLC from…”
BackgroundUPC2 Is Universally Essential for Azole Antifungal Resistance in Candida albicans
Vasicek, E. M., Berkow, E. L., Flowers, S. A., Barker, K. S., & Rogers, P. D. (2014) · Eukaryotic Cell · doi:10.1128/ec.00221-13 · Cited by 71 · cited 1×
“Upc2 is a global ergosterol-synthesis-related gene regulator contributing to FLC tolerance [40,41].”
BackgroundScott, E. M., Tariq, V. N., & McCrory, R. M. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.12.2610 · Cited by 69 · cited 2×
“…were repurposed to treat fungal infections [17,68]. of an old FDA-approved drugs previously identified for FLC adjuvants were fungal For example, ibuprofen, a non-steroidal anti-in fl ammatory drug, demonstrated synergy with FLC against C. albicans in vitro and in vivo [69–72]. infections [17,68].”
BackgroundMethodAre the Statins promising antifungal agents against invasive candidiasis?
Lima, W. G., Alves-Nascimento, L. A., Andrade, J. T., Vieira, L., de Azambuja Ribeiro, R. I. M., Thomé, R. G., dos Santos, H. B., Ferreira, J. M. S., & Soares, A. C. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.076 · Cited by 65 · cited 3×
“A In the case of rosuvastatin and FLC, the combination is effective against C. albicans [73]. species.”
BackgroundGerstein, A. C., Rosenberg, A., Hecht, I., & Berman, J. (2016) · Microbiology · doi:10.1099/mic.0.000295 · Cited by 63 · cited 2×
“The C. albicans FLC tolerance was evidenced by noticeable cell growth within the 25 µ g FLC inhibition zone in the disk diffusion assays [11,36].”
MethodChen, L., Zhang, L., Xie, Y., Wang, Y., Tian, X., Fang, W., Xue, X., & Wang, L. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115007 · Cited by 63 · cited 1×
“This issue is further compounded by increased drug-resistant fungal infections [2–4].”
BackgroundSelf-citationSong, J. L., Lyons, C. N., Holleman, S., Oliver, B. G., & White, T. C. (2003) · Medical Mycology · doi:10.1080/1369378031000137233 · Cited by 62 · cited 3×
“The inhibition is significantly enhanced in media with ethanol as the carbon source [78,79].”
BackgroundEpp, E., Vanier, G., Harcus, D., Lee, A. Y., Jansen, G., Hallett, M., Sheppard, D. C., Thomas, D. Y., Munro, C. A., Mullick, A., et al. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000753 · Cited by 61 · cited 3×
“…cyclosporine A (CsA), a calcineurin inhibitor, geldanamycin (GdA), an Hsp90 inhibitor, rapamycin, a target of rapamycin (TOR) inhibitor, and brefeldin A, a guanine nucleotide exchange factor inhibitor, have exhibited the capacity to induce fungicidal effects on FLC in laboratory studies [11,13–15].”
BackgroundSelf-citationRueda, C., Puig-Asensio, M., Guinea, J., Almirante, B., Cuenca-Estrella, M., Zaragoza, O., Padilla, B., Muñoz, P., Guinea, J., Paño Pardo, J. R., et al. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2016.09.016 · Cited by 58 · cited 2×
“In support, several studies found no positive relationship between FLC tolerance and mortality caused by IFIs after FLC treatment [24,25].”
BackgroundIbuprofen reverts antifungal resistance on Candida albicans showing overexpression of CDR genes
Ricardo, E., Costa-de-Oliveira, S., Silva Dias, A., Guerra, J., Rodrigues, A. G., & Pina-Vaz, C. (2009) · FEMS Yeast Research · doi:10.1111/j.1567-1364.2009.00504.x · Cited by 56
Eldesouky, H. E., Salama, E. A., Lanman, N. A., Hazbun, T. R., & Seleem, M. N. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00684-20 · Cited by 56 · cited 1×
“Previously, the drug repositioning approach has successfully identified FLC adju-vants [17–21].”
BackgroundEldesouky, H. E., Salama, E. A., Li, X., Hazbun, T. R., Mayhoub, A. S., & Seleem, M. N. (2020) · Scientific Reports · doi:10.1038/s41598-020-64571-7 · Cited by 55 · cited 1×
“For [73–75], including , simvastatin isolates of Candida A recent study demonstrated that pitavastatin as a potent azole chemosensitizing agent remarkably boosted the effects of FLC against azole-resistant Candida species [20].”
BackgroundGyetvai, Ã., Emri, T., Takács, K., Dergez, T., Fekete, A., Pesti, M., Pócsi, I., & Lenkey, B. (2006) · FEMS Yeast Research · doi:10.1111/j.1567-1364.2006.00097.x · Cited by 53
Impact of tolerance to fluconazole on treatment response in Candida albicans bloodstream infection
Levinson, T., Dahan, A., Novikov, A., Paran, Y., Berman, J., & Ben‐Ami, R. (2021) · Mycoses · doi:10.1111/myc.13191 · Cited by 50 · cited 5×
“However, recent studies have suggested high FLC tolerance levels contribute to persistent candidemia [11,12].”
BackgroundInfluentialCalcium-calcineurin signaling pathway in Candida albicans: A potential drug target
Li, W., Shrivastava, M., Lu, H., & Jiang, Y. (2021) · Microbiological Research · doi:10.1016/j.micres.2021.126786 · Cited by 47
Self-citationSimvastatin inhibits Candida albicans biofilm in vitro
Liu, G., Vellucci, V. F., Kyc, S., & Hostetter, M. K. (2009) · Pediatric Research · doi:10.1203/pdr.0b013e3181bd5bf8 · Cited by 43 · cited 1×
“Previous studies have indicated that statins, such as atorvastatin, lovastatin, and simvastatin, can suppress fungal ergosterol biosynthesis [50–52].”
BackgroundBen Othmène, Y., Monceaux, K., Belhadef, A., Karoui, A., Ben Salem, I., Boussabbeh, M., Abid-Essefi, S., & Lemaire, C. (2022) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2022.103919 · Cited by 43 · cited 1×
“The production of ROS is widely acknowledged to potentially initiate apoptosis [56].”
BackgroundNatural Polyketides Act as Promising Antifungal Agents
Wang, L., Lu, H., & Jiang, Y. (2023) · Biomolecules · doi:10.3390/biom13111572 · Cited by 42 · cited 1×
“While novel approaches may offer potential solutions for treating IFIs [5,6], azoles, functioning as inhibitors of lanosterol 14-α demethylase, continue to hold paramount importance as clinically approved antifungal medications for managing these infections [7].”
BackgroundSelf-citationChen, S. C.-A., Lewis, R. E., & Kontoyiannis, D. P. (2011) · Virulence · doi:10.4161/viru.2.4.16764 · Cited by 41 · cited 2×
“…cyclosporine A (CsA), a calcineurin inhibitor, geldanamycin (GdA), an Hsp90 inhibitor, rapamycin, a target of rapamycin (TOR) inhibitor, and brefeldin A, a guanine nucleotide exchange factor inhibitor, have exhibited the capacity to induce fungicidal effects on FLC in laboratory studies [11,13–15].”
BackgroundSircaik, S., Román, E., Bapat, P., Lee, K. K., Andes, D. R., Gow, N. A. R., Nobile, C. J., Pla, J., & Panwar, S. L. (2021) · Cellular Microbiology · doi:10.1111/cmi.13307 · Cited by 41 · cited 1×
“…( hac1 ∆ / hac1 ∆ ) (C1_06130C_A) and IRE1 ( ire1 ∆ / ire1 ∆ ) (C1_07970C_A) genes, which play important roles in endoplasmic reticulum (ER) stress [62], and the AGE3 ( age3 ∆ / age3 ∆ ) (C1_02260C_A) gene and a haploin-sufficient mutant of SEC14 ( SEC14 / sec14 ∆ )(C5_00480C_A), both of which are…”
Acute toxicity of bisphenol A in rats.
Pant, J., & Deshpande, S. B. (2012) · PubMed · Cited by 39
Cerivastatin-Induced Rhabdomyolysis
Rodríguez, M. L., Mora, C., & Navarro, J. F. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-7-200004040-00031 · Cited by 39
Wolf, J. M., Johnson, D. J., Chmielewski, D., & Davis, D. A. (2010) · Eukaryotic Cell · doi:10.1128/ec.00056-10 · Cited by 37
Costa-de-Oliveira, S., Miranda, I. M., Silva-Dias, A., Silva, A. P., Rodrigues, A. G., & Pina-Vaz, C. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05056-14 · Cited by 36 · cited 2×
“…were repurposed to treat fungal infections [17,68]. of an old FDA-approved drugs previously identified for FLC adjuvants were fungal For example, ibuprofen, a non-steroidal anti-in fl ammatory drug, demonstrated synergy with FLC against C. albicans in vitro and in vivo [69–72]. infections [17,68].”
BackgroundTashiro, M., Kimura, S., Tateda, K., Saga, T., Ohno, A., Ishii, Y., Izumikawa, K., Tashiro, T., Kohno, S., & Yamaguchi, K. (2012) · Medical Mycology · doi:10.3109/13693786.2011.610037 · Cited by 36 · cited 2×
“The inhibition is significantly enhanced in media with ethanol as the carbon source [78,79].”
BackgroundCombinatory effect of fluconazole and FDA-approved drugs against Candida albicans
Kaneko, Y., Fukazawa, H., Ohno, H., & Miyazaki, Y. (2013) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-013-0639-0 · Cited by 35
Lu, H., Li, W., Whiteway, M., Wang, H., Zhu, S., Ji, Z., Feng, Y., Yan, L., Fang, T., Li, L., et al. (2023) · mBio · doi:10.1128/mbio.02639-22 · Cited by 30
Self-citationWang, H., Ji, Z., Feng, Y., Yan, T., Cao, Y., Lu, H., & Jiang, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1101553 · Cited by 30 · cited 1×
“The plates were then incubated at 30 ◦ C for 48 h. Subsequently, the disk was transferred to a drug-free YPD plate, which was incubated at 30 ◦ C for 24 h and photographed [27].”
MethodSelf-citationArai, R., Sugita, T., & Nishikawa, A. (2005) · Mycoses · doi:10.1111/j.1439-0507.2004.01052.x · Cited by 29
Atorvastatin-induced cell toxicity in yeast is linked to disruption of protein isoprenylation
Callegari, S., McKinnon, R. A., Andrews, S., & de Barros Lopes, M. A. (2010) · FEMS Yeast Research · doi:10.1111/j.1567-1364.2009.00593.x · Cited by 28 · cited 3×
“These observations suggested that PIT targets HMG-CoA reductase encoded by the HMG1 (C1_03780C_A) gene in C. albicans [50].”
BackgroundFang, T., Xiong, J., Wang, L., Feng, Z., Hang, S., Yu, J., Li, W., Feng, Y., Lu, H., & Jiang, Y. (2023) · Antibiotics · doi:10.3390/antibiotics12121675 · Cited by 27 · cited 3×
“The determination of MFC followed the previously described method [29].”
MethodInfluentialSelf-citationIn vitro synergism of simvastatin and fluconazole against Candida species
Menezes, E. A., Vasconcelos Júnior, A. A. D., Silva, C. L. F., Plutarco, F. X., Cunha, M. D. C. D. S. O., & Cunha, F. A. (2012) · Revista do Instituto de Medicina Tropical de São Paulo · doi:10.1590/s0036-46652012000400003 · Cited by 25 · cited 2×
“In addition, simvastatin synergistically increased the antifungal e ff ect of FLC against some clinical isolates of Can ‐ dida species [77]. tropicalis [74,76].”
BackgroundMarine-Derived Metabolites Act as Promising Antifungal Agents
Hang, S., Lu, H., & Jiang, Y. (2024) · Marine Drugs · doi:10.3390/md22040180 · Cited by 23 · cited 1×
“While novel approaches may offer potential solutions for treating IFIs [5,6], azoles, functioning as inhibitors of lanosterol 14-α demethylase, continue to hold paramount importance as clinically approved antifungal medications for managing these infections [7].”
BackgroundSelf-citationChang, P., Wang, W., Igarashi, Y., Luo, F., & Chen, J. (2018) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2018.04.016 · Cited by 22 · cited 2×
“To establish another control strain with high FLC tolerance, we utilized a P ADH1 - UPC2 strain [42], in which the UPC2 gene (C1_08460C_A) was ectopically overexpressed under the regulation of the potent ADH1 promoter [31] (Figure S2B).”
MethodCerivastatin‐Induced Rhabdomyolysis: 11 Case Reports
Ravnan, S. L., Locke, C., Yee, W. P., & Haase, K. (2002) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.22.7.533.33674 · Cited by 20 · cited 1×
“Cerivastatin sodium was excluded from the LD50 evaluation documented association with severe rhabdomyolysis [45–47], while diglu-conate was removed Cerivastatin sodium was excluded from the LD50 evaluation due to its documented association with severe rhabdomyolysis [45–47], while chlorhexidine…”
MethodSevere Rhabdomyolysis and Cerivastatin—Gemfibrozil Combination Therapy
Roca, B., Calvo, B., & Monferrer, R. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1a383 · Cited by 20 · cited 1×
“Cerivastatin sodium was excluded from the LD50 evaluation documented association with severe rhabdomyolysis [45–47], while diglu-conate was removed Cerivastatin sodium was excluded from the LD50 evaluation due to its documented association with severe rhabdomyolysis [45–47], while chlorhexidine…”
MethodChaudhuri, B., Hämmerle, M., & Fürst, P. (1995) · FEBS Letters · doi:10.1016/0014-5793(94)01365-8 · Cited by 15 · cited 1×
“Removing the C-terminal autoinhibitory domain of Cmp1 can convert calcineurin into a constitutively activated complex [34,38,39].”
BackgroundXiong, J., Wang, L., Feng, Y., Zhen, C., Hang, S., Yu, J., Lu, H., & Jiang, Y. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122699 · Cited by 15 · cited 2×
“Many compounds have been found to make FLC fungicidal, such as GdA, CsA, brefeldin A, and so on [13,28,35,37].”
BackgroundMethodSelf-citationButts, A., Reitler, P., Ge, W., Fortwendel, J. R., & Palmer, G. E. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00504-18 · Cited by 14
Xiong, J., Wang, L., Feng, Z., Hang, S., Yu, J., Feng, Y., Lu, H., & Jiang, Y. (2024) · Antioxidants · doi:10.3390/antiox13020223 · Cited by 14 · cited 2×
“The ACT1 gene served as the internal control [26].”
BackgroundMethodSelf-citationFDA Regulations for Drug Development
Behrman, R. E., & Woodcock, J. (2010) · Science · doi:10.1126/science.329.5987.33-b · Cited by 8 · cited 1×
“…pressing need for the creation of safe and efficient novel pharmaceuticals to combat FLC tolerance in pathogenic fungi, the endeavor of developing an entirely new drug is a protracted and costly undertaking, necessitating a rigorous approval process by the Food and Drug Administration (FDA) [16].”
BackgroundInhibition of Candida albicans by Fluvastatin Is Dependent on pH
Schmidt, M., Dzogbeta, S., & Boyer, M. P. (2009) · Research Letters in Biochemistry · doi:10.1155/2009/151424 · Cited by 7 · cited 2×
“It has been observed that statins are beneficial for FLC against For example, fl uvastatin acts synergistically with FLC against Candida species [73–75], including FLC-resistant strains of C. albicans and C. tropicalis [74,76].”
Background
Cited by
Mechanisms of Azole Potentiation: Insights from Drug Repurposing Approaches
Xiong, J., Lu, H., & Jiang, Y. (2025) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.4c00657 · Cited by 20
Self-citationFang, T., Xiong, J., Huang, X., Fang, X., Shen, X., Jiang, Y., & Lu, H. (2024) · Microbiological Research · doi:10.1016/j.micres.2024.127964 · Cited by 17
Self-citationShi, Q., Yang, R., Yang, J., et al. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202422669 · Cited by 12
Li, W., Whiteway, M., Hang, S., Yu, J., Lu, H., & Jiang, Y. (2025) · Nature Communications · doi:10.1038/s41467-025-62131-z · Cited by 13
“Consequently, the cmp1 - aid Δ / cmp1 - aid Δ mutant, with the C-terminal 110 residues of Cmp1 deleted, exhibits high FLC tolerance 51 .”
Self-citationChai, X., Jiang, Y., Lu, H. J., & Huang, X. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1574990 · Cited by 9
Self-citation
Metadata
- Authors
- Li, W., Feng, Y., Feng, Z., Wang, L., Whiteway, M., Lu, H., & Jiang, Y.
- Affiliations
- Tongji University (CN)
- Concordia University (CA)
- Corresponding author
- Lu, Hui
- Jiang, Yuanying
- Venue
- Antioxidants
- Publisher
- MDPI AG
- Published
- 2024-05-29
- Volume
- 13
- Issue
- 6
- Pages
- 667
- ISSN
- 2076-3921 (ISSN-L)
- PMC
- PMC11200976
- OpenAlex
- W4399217048
- Cited by
- 14
- References
- 80
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 1
- FWCI
- 4.81
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Antioxidants (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Key Research and Development Program of China (2022YFC2303004, 2021YFC2300404, 82020108032, 202101070007-E00094)
- National Natural Science Foundation of China (2022YFC2303004, 2021YFC2300404, 82020108032, 202101070007-E00094)
- Innovation Program of Shanghai Municipal Education Commission (2022YFC2303004, 2021YFC2300404, 82020108032, 202101070007-E00094)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Keywords
- fluconazole, drug repurposing, fungicidal activity, drug synergy, HMG-CoA reductase inhibition, ubiquinone biosynthesis, reactive oxygen species, apoptosis, Golgi function, Candida albicans, invasive fungal infections, antifungal resistance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.